Pharmacological management of seizures post traumatic brain injury (MAST trial)

Cambridge University Hospitals NHS Foundation Trust0 个研究点目标入组 1,649 人开始时间: 2020年10月20日最近更新: 2021年3月22日

适应症

试验速览

暂无简介。

•MAST-DURATION:
•1. Patients aged =10 years with TBI managed in an NSU who have started on phenytoin or levetiracetam due to an acute symptomatic seizure during acute hospitalisation
•2. Patient or Legal Representative is willing and able to provide informed consent or in the absence of a legal representative, an Independent Healthcare Professional provides authorisation for patient enrolment
•MAST-PROPHYLAXIS:
•1. Patients aged =10 years, with TBI managed in an NSU without an acute symptomatic seizure
•2. Patient or Legal Representative is willing and able to provide informed consent or in the absence of a legal representative, an Independent Healthcare Professional provides authorisation for patient enrolment

•MAST-DURATION:
•1. Un-survivable injury
•2. Previous history of epilepsy
•3. Patients who are on an AED pre-TBI
•4. Patient who has been clinically prescribed an AED to treat PTS (other than phenytoin or levetiracetam) since current admission
•5. Any hypersensitivity to study drug selected or any of its excipients
•MAST-PROPHYLAXIS:
•1. Post-traumatic seizures
•2. Unsurvivable injury
•3. Previous history of epilepsy
•4. Patients who are on an AED pre-TBI
•5. Pregnancy or breastfeeding
•6. Any hypersensitivity to study drug (or hydantoins or pyrrolidone derivatives) or any of its excipients
•7. Time interval from the time of admission to NSU to randomisation exceeds 48 hours

发起方